Blockchain DMD Releases Analysis Positioning DMD V4 for Zero-Knowledge Integration

Blockchain DMD today announced the release of a new technical analysis examining the relationship between its DMD Diamond ...
The American Journal of Managed Care

Translating DMD Clinical Trial Findings to Real-World Application Discouraging

This analysis compared outcomes among patients who have Duchenne muscular dystrophy (DMD) and commercial insurance or Medicaid, focusing on how these differ between patients in clinical trials and ...
Yahoo Finance

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) – – ...
FierceBiotech

Santhera flunks DMD phase 3, prompting restructuring and withdrawal of approval application

Santhera Pharmaceuticals has stopped a phase 3 trial of Duchenne muscular dystrophy (DMD) drug idebenone after it failed an interim analysis. The setback prompted Santhera to outline plans to pull a ...
Business Wire

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
BioWorld

Suzhou Genassist announces pre-IND application for base-editing product GEN-6050 for DMD

Suzhou Genassist Therapeutic Co. Ltd. has announced its pre-IND application of its first base-editing product, GEN-6050, and acceptance by the FDA. GEN-6050 is an in vivo base-editing drug that ...
Morningstar

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy – U.S. FDA Study May Proceed ...